Publications by authors named "Dorsa Sadat Kiaei"
Article Synopsis
- - The ongoing phase II trial (NCT03363217) is investigating the effects of trametinib on pediatric low-grade gliomas (PLGG) and plexiform neurofibromas (PN), showing promising clinical responses and good tolerance in most patients.
- - Neurocognitive assessments were conducted on 36 patients with neurofibromatosis type 1 (NF1) before and after 72 weeks of trametinib treatment, revealing stable group performance but significant improvements in specific cognitive areas for some individuals.
- - The findings suggest that trametinib may have a positive impact on cognitive functioning in NF1 patients, particularly enhancing processing speed, visuo-motor skills, and verbal abilities, highlighting the need for neuro
Rationale And Objectives: Plexiform neurofibromas (PNs) are peripheral nerve tumors that occur in 25-50 % of patients with neurofibromatosis type 1. PNs may have complex, diffused, and irregular shapes. The objective of this work was to develop a volumetric quantification method for PNs as clinical assessment is currently based on unidimensional measurement.
View Article and Find Full Text PDF